Search results for "Protein"

showing 10 items of 21431 documents

Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors

2020

Abstract Aims Leucocyte telomere length (LTL) shortening is a marker of cellular senescence and associates with increased risk of cardiovascular disease (CVD). A number of cardiovascular risk factors affect LTL, but the correlation between elevated LDL cholesterol (LDL-C) and shorter LTL is debated: in small cohorts including subjects with a clinical diagnosis of familial hypercholesterolaemia (FH). We assessed the relationship between LDL-C and LTL in subjects with genetic familial hypercholesterolaemia (HeFH) compared to those with clinically diagnosed, but not genetically confirmed FH (CD-FH), and normocholesterolaemic subjects. Methods and results LTL was measured in mononuclear cells-d…

medicine.medical_specialtySettore MED/09 - Medicina InternaCellular ageingEpidemiologyHypercholesterolemiaCD34Cellular senescence030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciencesMice0302 clinical medicineInternal medicineLeukocytesMedicineAnimalsHumansProgenitor cellHaematopoiesi030304 developmental biologyLdl cholesterol0303 health sciencesbusiness.industryCholesterol LDLTelomere3. Good healthTelomereHaematopoiesisIncreased riskEndocrinologymedicine.anatomical_structureCHDTelomeresBone marrowCardiology and Cardiovascular MedicinebusinessFamilial hypercholesterolaemia
researchProduct

Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease

2014

Many placebo controlled trials and meta-analyses evaluated the efficacy of different drugs for the treatment of inflammatory bowel disease (IBD), including immunosuppressants and biologics. Their use is indicated in moderate to severe disease in non responders to corticosteroids and in steroid-dependent patients, as induction and maintainance treatment. Infliximab, as well as cyclosporine, is considered a second line therapy in the case of severe ulcerative colitis, or non-responders to intravenous corticosteroids. An adequate dosage and duration of therapy with thiopurines should be reached before evaluating their efficacy. Methotrexate is a valid option in patients with Crohn’s disease bu…

medicine.medical_specialtySettore MED/09 - Medicina InternaCombination therapyInflammatory bowel diseaseGastroenterologyimmunosuppresantbiologicsinflammatory bowel diseaseCrohn DiseaseGastrointestinal AgentsRisk FactorsInternal medicinemedicineimmunomodulators.optimization. treatmentHumansTopic HighlightBiological ProductsGastrointestinal agentCrohn's diseaseThiopurine methyltransferasebiologybusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisTacrolimusInfliximabSurgeryTreatment Outcomebiology.proteinColitis UlcerativeDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

The production of the oral mucosa of antiendomysial and anti-tissue-transglutaminase antibodies in patients with celiac disease: a review.

2010

Celiac disease (CD) is a lifelong, T cell—mediated enteropathy, triggered by the ingestion of gluten and related prolamins in genetically susceptible subjects, resulting in minor intestinal mucosal injury, including villous atrophy with crypt hyperplasia and intraepithelial lymphocytosis, and subsequent nutrient malabsorption. Although serological tests for antiendomysial (EMA) and anti—tissue transglutaminase (anti-tTG) autoantibodies are used to screen and follow up on patients with CD, diagnostic confirmation is still based on the histological examination of the small intestinal mucosa. Although the small intestinal mucosa is the main site of the gut involved in CD, other mucosal surface…

medicine.medical_specialtySettore MED/09 - Medicina InternaMalabsorptionGlutensTissue transglutaminaseBiopsyantiendomysial antibodieslcsh:Medicineoral biopsyReview Articlelcsh:TechnologyGastroenterologySensitivity and SpecificityGeneral Biochemistry Genetics and Molecular BiologySettore MED/28 - Malattie Odontostomatologicheanti–tissue transglutaminase antibodiesInternal medicineBiopsymedicineHumansEnteropathyOral mucosalcsh:ScienceGeneral Environmental ScienceAutoantibodiesSettore MED/12 - GastroenterologiaGastrointestinal tractTransglutaminasesbiologymedicine.diagnostic_testoral mucosalcsh:Tbusiness.industrylcsh:RMouth MucosaMuscle SmoothGeneral Medicinemedicine.diseaseCeliac Diseasemedicine.anatomical_structureceliac disease oral mucosa anti–tissue transglutaminase antibodies antiendomysial antibodies oral biopsy.Immunologybiology.proteinIntraepithelial lymphocytelcsh:QGliadinbusinessTheScientificWorldJournal
researchProduct

Matrix metalloproteinases in metabolic syndrome.

2011

Metabolic syndrome is commonly accompanied by an elevated cardiovascular risk with high morbidity and mortality. The alterations of the arterial vasculature begin with endothelial dysfunction and lead to micro- and macrovascular complications. The remodeling of the endothelial basal membrane, that promotes erosion and thrombosis, has a multifactorial pathogenesis that includes leukocyte activation, increased oxidative stress and also an altered matrix metalloproteinases (MMPs) expression. MMPs are endopeptidases which degrade extracellular matrix proteins, such as collagen, gelatins, fibronectin and laminin. They can be secreted by several cells within the vascular wall, but macrophages are…

medicine.medical_specialtySettore MED/09 - Medicina InternaMatrix metalloproteinaseGlobal HealthPathogenesisExtracellular matrixRisk FactorsDiabetes mellitusInternal medicineInternal MedicinemedicineHumansEndothelial dysfunctionMetabolic Syndromebiologybusiness.industryMETABOLIC SYNDROME MATRIX METALLOPROTEASES CARDIOVASCULAR RISKmedicine.diseaseMatrix MetalloproteinasesSurvival RateFibronectinOxidative StressEndocrinologyCardiovascular Diseasesbiology.proteinMorbidityMetabolic syndromebusinessDyslipidemia
researchProduct

Diastolic dysfunction and central obesity related hypertension: role of trasforming growth factor beta-1

2004

Abstract P-368 Key Words: Diastolic Dysfunction, Obesity Related Hypertension, Trasforming Growth Factor beta-1

medicine.medical_specialtySettore MED/09 - Medicina InternaMegalencephalic leukoencephalopathy with subcortical cystsmedicine.medical_treatmentDiastoleSettore MED/10 - Malattie Dell'Apparato RespiratorioOverweightLeft ventricular hypertrophyInternal medicineInternal MedicinemedicineSystolebiologybusiness.industryGrowth factorDiastolic Dysfunction Obesity Related Hypertension Trasforming Growth Factor beta-1Transforming growth factor betaDiastolic dysfunction HypertensionTrasforming factor beta 1medicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareObesityEndocrinologybiology.proteinCardiologymedicine.symptombusinessAmerican Journal of Hypertension
researchProduct

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct

Protein oxidation in metabolic syndrome

2013

Purpose: Oxidative stress plays a pivotal role in the pathogenesis of the metabolic syndrome and in the progression of its complications. Carbonylated proteins are a stable marker of severe oxidative stress because damage to the protein structure is irreversible and may cause an inhibition of their enzymatic activity or an increased susceptibility to proteolysis. There are few data regarding protein oxidation in metabolic syndrome, although elevated levels of carbonyl groups are often detected in subjects with obesity, diabetes mellitus, hypertension or dyslipidemia, well-known components of the metaboic syndrome. In particular, obesity, insulin resistance and diabetes mellitus are frequent…

medicine.medical_specialtySettore MED/09 - Medicina InternaProtein CarbonylationBiologyProtein oxidationmedicine.disease_causeProtein CarbonylationInsulin resistanceDiabetes mellitusInternal medicinemedicineAnimalsHumansMetabolic SyndromeInterleukin-6Tumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseOxidative Stressprotein oxidation metabolic syndromeEndocrinologyResistinMetabolic syndromeInsulin ResistanceDyslipidemiaOxidative stress
researchProduct

Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria

2017

The kidney is one of the major target organs of hypertension. Kidney damage represents a frequent event in the course of hypertension and arterial hypertension is one of the leading causes of end-stage renal disease (ESRD). ESRD has long been recognized as a strong predictor of cardiovascular (CV) morbidity and mortality. However, over the past 20 years a large and consistent body of evidence has been produced suggesting that CV risk progressively increases as the estimated glomerular filtration rate (eGFR) declines and is already significantly elevated even in the earliest stages of renal damage. Data was supported by the very large collaborative metaanalysis of the Chronic Kidney Disease …

medicine.medical_specialtySettore MED/09 - Medicina InternaRenal function030204 cardiovascular system & hematologyAsymptomatic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicine030212 general & internal medicineSubclinical infectionSettore MED/14 - NefrologiaKidneyCreatinineProteinuriabusiness.industryArterial hypertension • Blood pressure • Glomerular filtration rate • Microalbuminuria • Proteinuria • Subclinical renal disease • Early kidney injury • Target organ damage • Cardiovascular disease • Cardiovascular risk assessmentmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureEndocrinologychemistryCardiologyMicroalbuminuriamedicine.symptombusinessKidney disease
researchProduct

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retr…

2021

Abstract Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Ita…

medicine.medical_specialtySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]LipoproteinsGenetic diseaseTherapeuticsFamilial hypercholesterolemiaDiseaseLipoprotein apheresiLDLHyperlipoproteinemia Type IIchemistry.chemical_compoundLipoprotein apheresisRetrospective surveyInternal medicineCholesterol burden; Genetic disease; Homozygous hypercholesterolemia; LDL; Lipoprotein apheresis; Lomitapide; Therapeutics; Benzimidazoles; Homozygote; Humans; Lipoproteins; Retrospective Studies; Anticholesteremic Agents; Blood Component Removal; Hyperlipoproteinemia Type IImedicineHumansPharmacology (medical)Genetics (clinical)Retrospective Studiesmedicine.diagnostic_testbusiness.industryResearchAnticholesteremic AgentsHomozygous hypercholesterolemiaHomozygoteRGeneral Medicinemedicine.diseaseLomitapideLomitapidecholesterol burden; genetic disease; homozygous hypercholesterolemia; LDL; lipoprotein apheresis; lomitapide; therapeuticsCholesterol burdenchemistryCohortBlood Component RemovalMedicineTherapeutics.BenzimidazolesLipid profilebusinessLipoprotein apheresisCross nationalOrphanet Journal of Rare Diseases
researchProduct

Inflammation and Aortic Stiffness: An Individual Participant Data Meta‐Analysis in Patients With Inflammatory Bowel Disease

2017

Background The recent finding that aortic pulse wave velocity ( aPWV ) is increased in patients with inflammatory bowel disease may explain why the cardiovascular risk is increased despite the low prevalence of traditional cardiovascular risk factors. We aimed to test whether inflammation is associated with aortic stiffening in this setting after adjustment for major confounders and to perform subgroup analyses. Methods and Results A systematic literature search for aPWV in inflammatory bowel disease was performed using PubMed, Scopus, Web of Science, and Google Scholar databases (last accessed May 7, 2017). Inclusion criterion was peer‐reviewed publications on clinical studies reporting o…

medicine.medical_specialtySettore MED/09 - Medicina Internapulse wave velocitycardiovascular complicationsBlood SedimentationPulse Wave Analysis030204 cardiovascular system & hematologyStandard scoreInflammatory bowel diseaseLeukocyte Count03 medical and health sciencesVascular Stiffness0302 clinical medicineCrohn DiseaseRisk FactorsInternal medicinemedicineHumansArterial stiffness; Cardiovascular complications; Crohn's disease; Inflammation; Pulse wave velocity; Ulcerative colitis; Cardiology and Cardiovascular Medicine030212 general & internal medicineulcerative colitisInflammationSystematic Review and Meta‐AnalysisCrohn's diseasemedicine.diagnostic_testbusiness.industryMeta Analysisinflammation aortic stiffnessPrognosismedicine.diseaseUlcerative colitisConfidence intervalCrohn's diseaseC-Reactive Proteinarterial stiffnessCardiovascular DiseasesMeta-analysisErythrocyte sedimentation rateMultivariate AnalysisHypertensionLinear ModelsPhysical therapyArterial stiffnessColitis UlcerativeInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of the American Heart Association
researchProduct